MSQ Ventures and BioAroundWorld were thrilled to have presented the second installment of our webinar series “Global Development of Targeted Protein Degradation & Partnership Opportunities - Part 2." Our distinguished panel of experts provided unparalleled insights and viewpoints on cutting-edge research on TPD, which had seen increasing private and public funding in that space.

Unveiling What's New, Expert Insights and Viewpoints in Targeted Protein Degradation (TPD) PART 2

Moderator: Echo Hindle-Yang, President & CEO, MSQ Ventures 
Speakers: 
Nikhil Mutyal Ph.D., Executive Director, BD&L, Merck 
Randy Teel, SVP of corporate and BD, Arvinas 
Lily Zou, CEO, Degron Therapeutics 
Sahm Nasseri, CBO, Biotheryx, Inc.

Key Highlights: 

• Sharing by Nikhil Mutyal Ph.D., Executive Director, BD&L of Merck on global TPD partnership opportunities, and the $1 billion early discovery and development deal with Amphista Therapeutics Limited 

• Technology highlights and Company presentations of emerging TPD stars - including Arvinas, Degron Therapeutics, Biotheryx, Inc. 

• Highlight emerging deal structures, ‘platform collaboration’ vs. ‘licensing as partnership’ strategies and collaborations beyond oncology 

• Testimonial sharing by MSQ Ventures on cross-border transactions including licensing, M&A, fundraising, joint ventures, and other strategic partnerships.